Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18892026 | 0.86 | — | — | |
| SCHEMBL17705201 | 0.81 | ALOX5AP (0.31) | — | |
| Hydrochloric Acid SCHEMBL16296597 | 0.78 | GAA (0.35) | SLC6A4HTR2AGAA | |
| SCHEMBL17705198 | 0.77 | KDM4E (0.33) | SLC6A4SLC6A2SLC6A3HTR2AKDM4E | |
| SCHEMBL16296567 | 0.76 | HTR2A (0.30) | HTR2A | |
| SCHEMBL13159521 | 0.69 | ADRA2B (0.44) | SLC6A4SLC6A2SLC6A3HTR2AKDM4E | |
| SCHEMBL4525352 | 0.67 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3HTR2AKDM4E | |
| SCHEMBL16737984 | 0.65 | MEP1B (0.31) | — | |
| SCHEMBL17705194 | 0.65 | ALOX5AP (0.32) | — | |
| SCHEMBL18892023 | 0.64 | SCN5A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | SLC6A4 4618/4885SLC6A2 4567/4885SLC6A3 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.